NASDAQ: ZVSAZyversa Therapeutics Inc Stock
$1.51+0.11 (+7.86%)
Updated Jan 23, 2025
ZVSA Price
$1.51
Fair Value Price
N/A
Market Cap
$3.54M
52 Week Low
$0.98
52 Week High
$25.00
P/E
0x
P/B
0.5x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$21.33M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.76
Operating Cash Flow
-$9M
Beta
0.48
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ZVSA Overview
Larkspur Health Acquisition Corporation is a "blank check" company formed to effect mergers, stock purchases, or similar combinations with one or more businesses. It targets the biotech sector in the U.S. Larkspur Health Acquisition was incorporated in 2021 and is headquartered in Bridgewater, NJ.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ZVSA's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
F
Value
C
Growth
F
Momentum
B
Sentiment
C
Safety
D
Financials
F
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ZVSA
Ranked#269 of 556
Ranked#269 of 556
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.14 | A | |
| $122.48 | A | |
| $5.98 | A |
Be the first to know about important ZVSA news, forecast changes, insider trades & much more!
ZVSA News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ZVSA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ZVSA is good value based on its earnings relative to its share price (0x), compared to the US market average (30.03x)
P/E vs Market Valuation
ZVSA is good value based on its earnings relative to its share price (0x), compared to the US Biotechnology industry average (-205.94x)
P/E vs Industry Valuation
ZVSA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
There are 30 more ZVSA due diligence checks available for Premium users.
Valuation
ZVSA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
-205.94x
Market
30.03x
ZVSA is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
ZVSA is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
ZVSA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.5x
Industry
4.95x
ZVSA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ZVSA's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.4M
Profit Margin
0%
ZVSA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$19.4M
Liabilities
$12.4M
Debt to equity
1.76
ZVSA's short-term liabilities ($11.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ZVSA's long-term liabilities ($854.62k) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ZVSA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$644.4k
Investing
$0.0
Financing
$647.8k
ZVSA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ZVSA vs Biotech Stocks
Zyversa Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.